Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis.

2015

SummaryBackground It is unclear whether the course of cirrhosis and its prognosis are related to the amount of collagen in the liver. Aim To determine whether fibrosis, assessed by collagen proportionate area (CPA) in patients with compensated cirrhosis, is associated with the presence of oesophageal varices, and predict disease decompensation during the follow-up period. Methods We prospectively evaluated 118 consecutive patients with compensated cirrhosis to correlate fibrosis, assessed by CPA in liver biopsies, with the presence of oesophageal varices (OV) and with the rate of liver decompensation (LD) development during a median follow-up of 72 months. Results At baseline 38 (32.2%) pat…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBiopsyEsophageal and Gastric VaricesGastroenterologySeverity of Illness IndexSex FactorsFibrosisInternal medicineHypertension PortalmedicineHumansPharmacology (medical)DecompensationProspective StudiesAgedHepatologyReceiver operating characteristicbusiness.industryProportional hazards modelGastroenterologyAge FactorsHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisFibrosisCPAROC CurvePortal hypertensionFemaleCollagenbusinessVaricesLiver FailureAlimentary pharmacologytherapeutics
researchProduct

SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C

2009

The staging of liver fibrosis is pivotal for defining the prognosis and indications for therapy in hepatitis C. Although liver biopsy remains the gold standard, several noninvasive methods are under evaluation for clinical use. The aim of this study was to validate the recently described sequential algorithm for fibrosis evaluation (SAFE) biopsy, which detects significant fibrosis (≥F2 by METAVIR) and cirrhosis (F4) by combining the AST-to-platelet ratio index and Fibrotest-Fibrosure, thereby limiting liver biopsy to cases not adequately classifiable by noninvasive markers. Hepatitis C virus (HCV) patients (2035) were enrolled in nine locations in Europe and the United States. The diagnosti…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBiopsyGastroenterologyFibrosisInternal medicineBiopsymedicineHumansLiver biopsy chronic hepatitia CNeoplasm StagingRetrospective StudiesHepatitisSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryHepatitis CHepatitis C ChronicMiddle AgedHepatologymedicine.diseaseLiver biopsyFemaleHepatic fibrosisbusinessAlgorithmsHepatology
researchProduct

Treatment of small hepatocellular carcinoma associated with cirrhosis by percutaneous ethanol injection. A trial with a comparison group.

1997

Ethanol injection has been reported to be effective in the treatment of hepatocellular carcinoma, but no controlled randomized trials have been performed. We therefore performed a trial comparing ethanol injection with an untreated, matched historical comparison group in the treatment of hepatocellular carcinoma.From 1992 to 1993, 35 patients (14 Child's A and 21 Child's B cirrhosis) with small (4 cm) hepatocellular carcinoma associated with cirrhosis were treated by ethanol injection. Each patient was matched with an untreated case (followed up during the period 1984-89) for variables known to have independent prognostic value (age, Child's classification, number of lesions, alpha-fetoprot…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentEthanol InjectionGastroenterologylaw.inventionRandomized controlled triallawInternal medicinemedicineHumansChemotherapyEthanolbusiness.industryLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseConfidence intervalSurvival RateHepatocellular carcinomaCase-Control StudiesSolventsFemalePercutaneous ethanol injectionComplicationbusinessScandinavian journal of gastroenterology
researchProduct

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model.

2000

OBJECTIVE: Percutaneous ethanol injection may prolong the survival of patients with small hepatocellular carcinoma associated with cirrhosis. The aim was to identify prognostic factors of survival and of local recurrence, as well as separate new lesions. METHODS: We performed Cox regression analysis in 115 consecutive patients with hepatocellular carcinoma (81 Child-Pugh class A, 34 Child-Pugh class B) treated by percutaneous ethanol injection. The validity of the model was tested by comparing predicted and observed survival in 105 independent patients from an external series. RESULTS: Overall survival rates were 89%, 63%, and 43% at 1, 2, and 3 yr, respectively. The 1-, 2-, and 3-yr surviv…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentInjections IntralesionalSmall-cell carcinomaGastroenterologyLiver Function TestsInternal medicinemedicineCarcinomaHumansSurvival rateSerum AlbuminAgedHepatologymedicine.diagnostic_testEthanolbusiness.industryProportional hazards modelLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseasedigestive system diseasesSurgerySurvival RateHepatocellular carcinomaFemalePercutaneous ethanol injectionbusinessLiver function testsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

The Role of Liver in Determining Serum Colon-Derived Uremic Solutes.

2015

Evidence has shown that indoxyl sulfate (IS) and p-cresyl sulfate (PCS) may be alternative predictors of clinical outcomes in chronic kidney disease (CKD). Both toxins are derived from the gastrointestinal tract and metabolised in the liver. However, it is unclear whether the liver affects the production of IS and PCS. Here, we explore the association between IS and PCS levels in liver cirrhosis and a CKD-based cohort (N = 115). Liver and kidney function was assessed and classified by a Child-Pugh score (child A–C) and a modified version of the Modification of Diet in Renal Disease (MDRD) equation (Stages 1–4), respectively. An animal model was also used to confirm the two toxin levels in a…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisColonlcsh:MedicineUrineSulfuric Acid EstersKidneyGastroenterologyCohort StudiesRats Sprague-DawleyCresolsInternal medicinemedicineAnimalsHumansRenal Insufficiency Chroniclcsh:ScienceAgedUremiaKidneyGastrointestinal tractMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RKidney metabolismMiddle Agedmedicine.diseaseUremiahumanitiesRatsGastrointestinal TractDisease Models Animalmedicine.anatomical_structureEndocrinologyTreatment OutcomeLiverMultivariate AnalysisLinear Modelslcsh:QFemaleLiver function testsbusinessIndicanKidney diseaseResearch ArticlePloS one
researchProduct

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial

2007

Abstract BACKGROUND/AIMS: Risks and benefits of antiviral therapy in HCV cirrhosis with portal hypertension are poorly known. METHODS: We performed a randomized controlled trial in 102 HCV patients with compensated cirrhosis and portal hypertension: 51 received 1 microg/kg/week of Pegylated-interferon alpha-2b and 51 Pegylated-interferon plus 800 mg/day of ribavirin up to 52 weeks. RESULTS: By intention-to-treat analysis, five patients on monotherapy and eleven on combination therapy achieved a sustained virological response (9.8% vs. 21.6%, p=0.06). The response was more frequent for genotypes 2 or 3 than genotype 1 (66.6% vs. 11.3%, p=0.001). Genotype 1, who had low viral load at start of…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisCombination therapyAlpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsPolyethylene GlycolsCirrosi epatica da HCV terapia antivirale.chemistry.chemical_compoundPharmacotherapyInternal medicineHypertension PortalRibavirinmedicineHumansAgedHepatologybusiness.industryRibavirinInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryTreatment OutcomechemistryPortal hypertensionRNA ViralDrug Therapy CombinationbusinessViral load
researchProduct

The duodenum in liver cirrhosis: endoscopic, morphological and clinical findings.

1991

Endoscopic studies were performed to determine whether changes occurred in the duodenum related to portal hypertension in patients with liver cirrhosis. The total of 271 patients studied were subdivided into three groups: 83 patients with liver cirrhosis and portal hypertension, 53 with liver cirrhosis but no portal hypertension, and 135 controls. In the duodenum of cirrhotic patients with portal hypertension several changes were observed on endoscopy that were also present in the other two groups. Atrophy and vascular malformations, however, were present only in the duodenum of cirrhotic patients with portal hypertension, although in only a few patients and with statistical significance on…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisDuodenumGastroenterologyAtrophyEsophageal varicesDuodenitisInternal medicineHypertension PortalmedicineHumansEndoscopy Digestive SystemIntestinal MucosaAgedmedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseEndoscopymedicine.anatomical_structureDuodenumPortal hypertensionBlood VesselsFemaleComplicationbusinessEndoscopy
researchProduct

Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis

2008

Indirect methods to predict the presence of esophageal varices (EV) in patients with cirrhosis are not sensitive enough to be used as a surrogate for endoscopy. We tested the effectiveness of liver stiffness measurement (LSM) by transient elastography and the presence of insulin resistance (IR), a marker associated with fibrosis progression, in the noninvasive prediction of portal hypertension. One hundred four consecutive patients with newly diagnosed Child A hepatitis C virus (HCV) cirrhosis underwent upper gastrointestinal endoscopy to search for EV. Clinical, anthropometric, biochemical, ultrasonographic, and metabolic features, including IR by the homeostasis model assessment (HOMA), a…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisEsophageal and Gastric VaricesGastroenterologyEsophageal varicesInsulin resistanceRisk FactorsDiabetes mellitusInternal medicineHypertension PortalmedicineHumansEndoscopy Digestive SystemProspective StudiesAgedHepatologyPlatelet Countbusiness.industryHepatitis CMiddle AgedHepatologymedicine.diseaseHepatitis CLiverROC CurveMultivariate AnalysisDisease ProgressionElasticity Imaging TechniquesPortal hypertensionFemaleInsulin ResistanceTransient elastographybusinessSpleenHepatology
researchProduct

Clinical value of increased serum creatinine concentration as predictor of short-term outcome in decompensated cirrhosis

2004

The purpose of this study was to assess whether serum creatinine concentration alone or associated with other biological parameters was an independent predictor of short-term mortality in patients with decompensated cirrhosis.A total of 212 consecutive episodes of decompensated cirrhosis in patients admitted to the hospital between January 1999 and December 2001 were reviewed retrospectively. Depending on a serum creatinine concentration equal to or greater than 1.5 mg/dL at the time of admission, patients were divided into decompensated cirrhosis with renal failure (101 episodes in 59 patients, aged 69.8 +/- 10 years) and without renal failure (111 episodes in 61 patients, aged 64.5 +/- 13…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisGastroenterologyLiver diseasechemistry.chemical_compoundInternal medicinemedicineHumansDecompensationHospital MortalityRenal InsufficiencySurvival rateSerum AlbuminAgedCreatinineModels Statisticalbusiness.industryGastroenterologyBilirubinMiddle AgedPrognosismedicine.diseaseDecompensated cirrhosisSurgerySurvival RateTreatment OutcomeROC CurveEl NiñochemistryCreatinineFemalebusinessBiomarkersKidney diseaseScandinavian Journal of Gastroenterology
researchProduct

Uncommon imaging evolutions of focal liver lesions in cirrhosis.

2019

Objective: The purpose of this article is to describe and illustrate uncommon imaging evolutions of benign (i.e., cyst, hemangioma, focal nodular hyperplasia-like nodules, and hepatic angiomyolipoma) and malignant (i.e., HCC and non HCC malignancies) lesions in a cirrhotic liver. The content highlights relevant pathogenesis and imaging clues for proper differential diagnosis. Revision of prior imaging and knowledge of these scenarios may help the abdominal radiologist to reach a noninvasive diagnosis and direct the patient to the most appropriate clinical management. Conclusion: Uncommon imaging evolutions of focal liver lesions in cirrhosis may represent a challenge for the abdominal radio…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatic AngiomyolipomaHepatocellular carcinomaUrologyLiver neoplasm030218 nuclear medicine & medical imagingLiver cirrhosiHemangioma03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingCystComputed tomographyAgedAged 80 and overRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryCystsLiver DiseasesLiver NeoplasmsGastroenterologyMagnetic resonance imagingHepatologyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingLiverFocal Nodular Hyperplasia030220 oncology & carcinogenesisHepatocellular carcinomaFemaleRadiologyDifferential diagnosisbusinessTomography X-Ray ComputedAbdominal radiology (New York)
researchProduct